Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGC101 for no-option critical limb ischemia in peripheral arterial disease
2024-516665-36-00Phase 2Authorised
- Sponsor
- BioGenCell
- Start
- Jan 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in arteriosclerosis obliterans and chronic limb-threatening ischemia (CLTI) comparing BGC101 arm with Placebo arm (2 arms). Primary endpoints: Safety endpoints, Major amputation rate and 1 more. Planned start Jan 2024; status: authorised.
02
Drugs
BGC101
03
Conditions
arteriosclerosis obliteranschronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on 2024-516665-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516665-36-00.